Valuation: TaiGen Biopharmaceuticals Holdings Limited

Market Cap 6.25B 190M 172M 159M 144M 271M 17.9B 280M 1.91B 758M 9.56B 713M 697M 30.36B P/E 2024
-213x
P/E 2025 223x
Enterprise Value 5.27B 160M 145M 134M 121M 228M 15.1B 236M 1.61B 640M 8.07B 601M 588M 25.61B EV / Sales 2024
48.2x
EV / Sales 2025 33x
Free-Float
53.89%
Yield 2024 *
-
Yield 2025 -
08-26 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-05 InSilico Out-licensed Drug ISM4808 Begins Clinical Trial MT
11-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-09-21 TaiGen Biopharmaceuticals Holdings Limited(TPEX:4157) added to S&P Global BMI Index CI
25-08-19 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-07-31 TaiGen Biopharmaceuticals Holdings Limited(TPEX:4157) dropped from S&P Global BMI Index CI
25-05-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-14 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-01 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-14 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
1 day+6.81%
1 week+12.42%
Current month+4.90%
1 month-1.57%
3 months-0.68%
6 months-4.98%
Current year-34.48%
1 week 7.86
Extreme 7.86
8.78
1 month 7.39
Extreme 7.39
9.17
Current year 7.39
Extreme 7.39
16.4
1 year 7.39
Extreme 7.39
16.4
3 years 7.39
Extreme 7.39
17.25
5 years 7.39
Extreme 7.39
21.05
10 years 7.39
Extreme 7.39
38.7
Manager TitleAgeSince
Chief Executive Officer - 2019-01-01
Director of Finance/CFO - 2016-03-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman - 2001-03-31
Director/Board Member - 2013-04-28
Director/Board Member - 2009-03-02
Change 5-day change 1-year change 3-year change Capi.($)
+6.81%+12.42%-7.19%-40.27% 190M
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.92%+2.67%+31.13%+71.00% 429B
Weighted average by Cap. +0.54%+3.26%+37.70%+96.49%

Financials

2024 2025
Net sales 151M 4.58M 4.15M 3.84M 3.46M 6.52M 432M 6.75M 46.09M 18.27M 231M 17.18M 16.81M 732M 259M 7.88M 7.14M 6.61M 5.96M 11.24M 743M 11.63M 79.38M 31.47M 397M 29.58M 28.96M 1.26B
Net income -38.58M -1.17M -1.06M -983K -887K -1.67M -111M -1.73M -11.8M -4.68M -59.04M -4.4M -4.31M -187M 45.18M 1.37M 1.24M 1.15M 1.04M 1.96M 129M 2.03M 13.82M 5.48M 69.13M 5.15M 5.04M 219M
Net Debt -961M -29.2M -26.46M -24.48M -22.08M -41.62M -2.75B -43.08M -294M -117M -1.47B -110M -107M -4.67B -978M -29.7M -26.91M -24.89M -22.46M -42.33M -2.8B -43.82M -299M -119M -1.5B -111M -109M -4.75B
Projected Income Statement - Annual - TaiGen Biopharmaceuticals Holdings Limited
Logo TaiGen Biopharmaceuticals Holdings Limited
Taigen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs. The Company operates through two segments. The New Drug Research and Development and Drug Sales segment is mainly engaged in the research, development, manufacturing and sales of various new drugs and cell preparations. The Other segment provides medical technology consulting services. The Company's main products are Nemonoxacin and TG-100. Nemonoxacin is mainly used for nosocomial pneumonia infections, diabetic foot infections, urinary tract infections and complicated skin infections. TG-100 is mainly used for type A, type B influenza and avian influenza.
Employees
-
Date Price Change Volume
26-11-13 NT$8.780 +6.81% 1,577,429
26-11-12 NT$8.220 -0.84% 681,836
26-11-11 NT$8.290 +2.09% 694,246
26-11-10 NT$8.120 -0.12% 674,945
26-11-09 NT$8.130 +4.10% 574,096
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 4157 Stock